Catheter Precision Initiates LockeT Compare Study to Evaluate Safety Profile

Catheter Precision has announced the start of enrollment for the LockeT Compare Study, which will evaluate the safety profile of the LockeT suture retention device compared to internal closure devices. The study aims to enroll up to 100 patients and is expected to show that LockeT reduces thrombotic episodes and improves patient safety. Catheter Precision's LockeT device is a Class 1 device registered with the FDA and has received CE Mark approval.

Catheter Precision Inc. (NYSE: VTAK) has initiated enrollment for the LockeT Compare Study, a single-center, physician-initiated trial aimed at evaluating the safety profile of the LockeT suture retention device compared to internal closure devices. The study, which began with the enrollment of its first three patients, is expected to enroll up to 100 participants and is designed to assess the safety and potential benefits of LockeT in managing groin complications after cardiac catheter procedures [1].

The LockeT Compare Study is particularly significant as it builds on the company's previous clinical data, which have demonstrated the safety, effectiveness, and cost reduction benefits of LockeT. The device, which creates hemostasis externally, may potentially reduce thrombotic episodes compared to internal closure mechanisms, thereby improving patient safety [1].

Catheter Precision, an innovative U.S.-based medical device company, is focused on developing technologically advanced products for the cardiac electrophysiology market. The company's CEO, David Jenkins, stated that effective groin management after a cardiac catheter procedure is as crucial as the procedure outcomes. He expressed confidence that the LockeT Compare Study will show a reduction in thrombotic episodes compared to internal closure devices, further enhancing patient safety [1].

LockeT is a Class 1 device registered with the FDA and has received CE Mark approval, indicating its regulatory compliance for both U.S. and European markets. The device is intended to assist in wound closure after percutaneous venous punctures [1].

The positive regulatory news surrounding LockeT has led to a significant increase in Catheter Precision's stock price. Shares of the company have surged over 65%, reaching $4.36, following the announcement of LockeT's UK regulatory approval and CE Mark for European distribution [2].

The LockeT Compare Study is set to provide further insight into the potential advantages of LockeT, which could have a substantial impact on the cardiac catheterization market. As the study progresses, investors and financial professionals will be closely monitoring the results to assess the device's efficacy and potential market penetration.

References:
[1] https://www.stocktitan.net/news/VTAK/catheter-precision-announces-the-start-of-enrollment-for-the-locke-t-nk7dprg8u59o.html
[2] https://www.nasdaq.com/articles/catheter-precisions-locket-wound-closure-device-approved-uk-shares-soar-over-65